An observational study in Drug Hypersensitivity and DRESS Syndrome, sponsored by University Hospital, Lille. Recruiting at 11 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by University Hospital, Lille · Observational
Drug Hypersensitivity Syndrome or DRESS for "Drug Reaction with Eosinophilia and Systemic Symptoms" is a serious drug allergy which can be life-threatening for patients with serious organ damage. The pathophysiology of DRESS is still not fully understood. In particular, no study has focused on the characterization of eosinophils, while paradoxically eosinophilia is one of the diagnostic criteria. Likewise, there is no data about the origin of eosinophils and few data are available concerning immune polarization of T-cells or the involvement of innate lymphoid cells type 2 in the recruitment of eosinophils. Our preliminary data on increase activation markers membrane expression of cutaneous eosinophils suggest that this approach could allow the identification of endotypes in which eosinophils are involved and contribute to organ damages. The correlation between tissue infiltration of eosinophils and their degree of activation would then justify the development of targeted therapeutic strategies in DRESS syndrome (anti-IL-5 therapy?). The aim of the project is: 1) Evaluate the activation status of circulating and cutaneous eosinophils in patients with DRESS compared with drug induced maculopapular exanthema without or with eosinophilia (but do not fulfill DRESS criteria) and healthy subjects; 2) Understand the pathophysiological mechanisms at the origin of this eosinophilia.
57 studies on the registry are indexed under Drug Hypersensitivity; 18 are open to participants now.
This study's planned enrollment of 80 is below the median of 204 across 30 observational studies indexed under Drug Hypersensitivity.
Browse Drug Hypersensitivity studies →University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient with drug induced rash (DRESS, maculopapular exanthema) and healthy patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group 1 (DRESS): adult with a diagnosis of DRESS based on the following four criteria:
Groups 2 and 3 (Drug induced maculopapular exanthema without or with eosinophilia).
Group 2 (MPE without eosinophilia): blood eosinophils \< 500 / mm3
Group 3 (MPE with eosinophilia): blood eosinophils ≥ 500 / mm3
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients with drug induced maculopapular exanthema (MPE) with eosinophilia
Activation status of circulating eosinophils by flow cytometry
Time frame: Baseline
Mean fluorescence intensity of CCR3 and IL-5R markers
Time frame: Baseline
Percentage of Th2 polarized T cells
Time frame: Baseline
Percentage of ILC2
Time frame: Baseline
Serum levels (ELISA) of inflammatory markers
Time frame: Baseline
Correlation between the number of activated circulating eosinophils, area degranulation and severity of DRESS
Time frame: Baseline
Density of extracellular granules (degranulation area and number / mm2) on skin biopsies
Time frame: Baseline
NGS analysis of rearrangements of TCR (T cell receptor)
Time frame: Baseline and 3 months
Started Jul 2020 (actual). Primary completion is estimated for Oct 2027, 87 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.